Fig. 2: Cellular levels of nucleotide sugars and LLOs in mammary carcinoma cell lines with different HA-producing abilities. | Cell Death & Disease

Fig. 2: Cellular levels of nucleotide sugars and LLOs in mammary carcinoma cell lines with different HA-producing abilities.

From: Tolerable glycometabolic stress boosts cancer cell resilience through altered N-glycosylation and Notch signaling activation

Fig. 2

A, B Ion-pair reversed-phase HPLC profiles (A) and cellular levels (B) of nucleotide sugars in HA-low Has2+Neo and HA-high Has2ΔNeo cells. Data are the mean ± SD from n = 3. Two-tailed Student’s t-test. *p < 0.05, **p < 0.01. C Schematic diagram of nucleotide sugar biosynthesis. UDP-GlcNAc and GDP-Man are synthesized de novo from a common glycolytic intermediate, fructose-6-phosphate (Fru-6P), in the hexosamine biosynthetic pathway (orange) and GDP-Man biosynthetic pathway (blue), respectively. UDP-GlcUA is produced by a three-step reaction (yellow‒green): conversion of glucose-6-phosphate (Glc-6P) into glucose-1-phosphate (Glc-1P), conversion of Glc-1P into UDP-Glc, and oxidation of UDP-Glc. UDP-GlcNAc and UDP-GlcUA are utilized for HA biosynthesis. D Schematic diagram of LLO biosynthesis. The assembly of LLO precursors is initiated by the addition of GlcNAc-phosphate to dolichol-phosphate (Dol-P) from UDP-GlcNAc on the cytosolic face of the ER membrane. After translocation into the ER lumen, the mature form of LLOs, Glc3Man9GlcNAc2-PP-Dol, is synthesized and transferred onto asparagine residues within nascent polypeptide acceptors by the oligosaccharyltransferase (OST) complex. E‒G HPLC profiles (E) and quantification (F, G) of LLO glycans prepared from Neu, Has2+Neo, and Has2ΔNeo cells. Data are the mean ± SD from n = 4. Tukey’s test. *p < 0.05, **p < 0.01.

Back to article page